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Abstract
Purpose A phase II, open-label, dose-finding, randomized
study was performed to evaluate the recommended dose of
pegfilgrastim in Japanese breast cancer patients.
Methods Patients received 1.8, 3.6, or 6.0 mg of pegfilgrastim
once per chemotherapy cycle for up to 6 cycles. Patients re-
ceived docetaxel, doxorubicin, and cyclophosphamide (TAC)
therapy followed by pegfilgrastim on the next day.
Results Pegfilgrastim was administered to 87 women with
stage II/III invasive breast carcinoma. The duration of grade
4 neutropenia in the first cycle, the primary endpoint, was 2.2
±0.9 days, 1.5±0.9 days, and 1.4±0.7 days in the 1.8, 3.6, and
6.0 mg groups, respectively. This finding indicated that
pegfilgrastim efficacy peaked at 3.6 mg. Pegfilgrastim doses
up to 6.0 mg were considered safe.
Conclusion A 3.6-mg pegfilgrastim dose may be safe and
effective for Japanese patients. A confirmatory study is re-
quired to establish safety and efficacy at this dose for intensive
anti-cancer chemotherapy.
Keywords Pegfilgrastim . TAC chemotherapy . Breast
cancer . Febrile neutropenia . G-CSF . Granulocyte-colony
stimulating factor
Introduction
Febrile neutropenia (FN) is a clinical condition characterized
by the development of fever in association with neutropenia.
The risk of FN increases with the duration of neutropenia [1,
2]. Infection, often manifested by FN, may become serious
and potentially life threatening. Therefore, to prevent FN, che-
motherapy doses are often reduced or dose intervals are ex-
tended. However, reduced relative dose intensity may reduce
the efficacy of chemotherapy regimens, leading to decreased
survival rates, particularly in curative settings [3–7]. For these
reasons, granulocyte-colony stimulating factor (G-CSF) is
used to reduce the risk of chemotherapy-associated FN. G-
CSFmay improve therapeutic outcomes by helping anticancer
drugs to be administered at planned dosages and intervals.
Guidelines for the recommended use of G-CSF based on FN
risk have been established by the American Society of Clinical
Oncology, National Comprehensive Cancer Network, and Eu-
ropean Organization for Research and Treatment of Cancer
[8–10]. Prophylactic use of G-CSF is based on the intensity
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Dose response of pegfilgrastim in Japanese breast cancer patients
receiving six cycles of docetaxel, doxorubicin,
and cyclophosphamide therapy: a randomized controlled trial
of chemotherapy regimens and patient-specific risks and is
recommended for patients with a 20 % or greater risk of FN.
Pegfilgrastim is a drug with a polyethylene glycol (PEG)
molecule, approximate molecular weight of 20,000, covalent-
ly bound to the N-terminal residue of G-CSF (filgrastim).
Pegfilgrastim is produced by recombinant DNA technology
and expressed in Escherichia coli. PEG-modified protein is
known to decrease kidney clearance, inhibit protease-
mediated hydrolysis, and prolong serum half-life. The serum
half-life of pegfilgrastim has been reported to be 2 to 3 days,
which is longer than the approximately 3-h half-life of
filgrastim.
A placebo-controlled study in patients with early-stage
breast cancer showed that the incidence rates of FN were 17
and 1 % in the placebo and pegfilgrastim groups, respectively
[11]. Therefore, prophylactic pegfilgrastim can remarkably re-
duce the incidence of FN. Furthermore, pegfilgrastim has been
shown to reduce the incidence of FN-related hospitalizations
and the use of intravenous antibiotics to treat infection. In the
curative setting, highly myelosuppressive chemotherapy regi-
mens may be required to treat patients with early-stage breast
cancer. TAC, dose-dense doxorubicin plus cyclophosphamide
followed by paclitaxel, and TC (docetaxel plus cyclophospha-
mide) regimens are widely used in the clinical setting and have
been shown to result in favorable clinical outcomes.
While pegfilgrastim has been widely studied in the United
States and European populations, it has not been evaluated in
the Japanese population. Therefore, a phase II dose-finding
study of pegfilgrastim was performed in Japanese patients
with early-stage breast cancer. To evaluate the efficacy of
pegfilgrastim in this population, TAC therapy, a highly mye-
losuppressive chemotherapy that is used in the adjuvant treat-
ment of early stage breast cancer, was selected. The primary
endpoint of this study was the duration of severe (grade 4)
neutropenia in the first cycle (DSN).
Materials and methods
Patients
This study was conducted in accordance with the Declaration
of Helsinki. The institutional review boards of the participat-
ing centers approved the protocol. Informed consent was ob-
tained from all patients before beginning any study-related
procedures.
Women who met the following inclusion criteria were eli-
gible for study entry: aged 20–64 years of age;
pathohistological and clinical diagnosis of stage II or III pri-
mary invasive breast carcinoma; Eastern Cooperative Oncol-
ogy Group performance status ≤2; chemotherapy naïve; plan
to receive full-dose adjuvant or neoadjuvant TAC therapy;
absolute neutrophil count (ANC)≥2×109/L; platelet count
≥100×109/L; hemoglobin concentration ≥10 g/dL; aspartate
aminotransferase and alanine aminotransferase levels ≤2.5
times the upper limit of the normal range in each institute;
total bilirubin content ≤1.5 times the upper limit of the normal
range in each institute; creatinine level ≤1.5 mg/dL; left ven-
tricular ejection fraction ≥50%; and negative hepatitis B (hep-
atitis B surface antigen and hepatitis B core antibody) test
result within 3 months of enrollment. Patients with a history
of radiation therapy within 4 weeks of enrollment, history of
bone marrow or stem cell transplantation, or comorbid malig-
nancies other than breast cancer were excluded from the study.
Study design
This was a multicenter, randomized, open-label, dose-finding
study to evaluate the safety and efficacy of a single injection of
pegfilgrastim per chemotherapy cycle in Japanese patients.
Patients were randomized via a dynamic allocation method
and were assigned in a 1:1:1 ratio to each pegfilgrastim cohort
(1.8, 3.6, and 6.0 mg) after stratification according to chemo-
therapy status (neoadjuvant or adjuvant) and investigational
site (Fig. 1).
Chemotherapy treatment
On day 1 of each chemotherapy cycle, patients received an
intravenous infusion of doxorubicin (50 mg/m2), followed by
intravenous infusions of cyclophosphamide (500 mg/m2) and
docetaxel (75 mg/m2). Chemotherapy was repeated every
3 weeks for up to 6 cycles.
Full-dose chemotherapy was administered on day 1 of the
next cycle to patients who met the following criteria: ANC
≥1.5×109/L, platelet count ≥100×109/L, hemoglobin concen-
tration ≥8 g/dL, aspartate aminotransferase and alanine ami-
notransferase levels ≤2.5 times the upper limit of the normal
Fig. 1 Study schema Superscript letter a indicates that pegfilgrastim
(KRN125) was administered subcutaneously (SC) 24 h after docetaxel
administration on day 2 of each cycle. Superscript letter b indicates that
chemotherapy cycle was defined as the interval from the day of TAC
(docetaxel, doxorubicin, and cyclophosphamide) initiation to the day
before the next TAC course. The maximum duration of each
chemotherapy cycle was 42 days
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range in each institute, total bilirubin content ≤1.5 times the
upper limit of the normal range in each institute, and creatinine
level ≤1.5 mg/dL. In addition, any adverse events, including
peripheral neuropathy, edema, constipation, and weight loss,
must have been cured completely or reduced to below grade
2. Any non-hematologic adverse events other than hair loss,
peripheral neuropathy, edema, weight loss, and constipation
must have been cured completely or reduced to grade 1. After
adverse event recovery to the appropriate level, chemotherapy
was resumed at the full dose administered in the previous cycle.
Patients whose chemotherapy was delayed for more than
3 weeks were eliminated from the study.
If any grade 3 or 4 critical adverse event, including FN,
prolonged neutropenia, thrombocytopenia, abdominal pain,
diarrhea, nausea, vomiting, or nerve disorder, occurred in the
previous cycle of TAC therapy, and dose reduction was
deemed necessary by the investigator, the dosage of each an-
ticancer drug was reduced 20 % in the next cycle. Dose re-
duction was allowed only once.
Supportive treatment consisted of 20mg of dexamethasone
administered intravenously on day 1 and 4 mg of dexameth-
asone administered orally twice daily on days 2 and 3. Pro-
phylactic antibiotics were prohibited in the first cycle of
chemotherapy.
Study treatment
On day 2 of each chemotherapy cycle (24 h after chemother-
apy completion), patients received a single subcutaneous in-
jection of pegfilgrastim at a fixed dose of 1.8 g, 3.6, or 6.0 mg.
G-CSF treatment was generally prohibited during the study
period. However, rescue G-CSF treatment was allowed only
when three consecutive days of concurrent fever (≥38 °C) and
grade 4 neutropenia occurred in cycle 1 or when three consec-
utive days of fever accompanied by ≥1 episode of grade 4
neutropenia occurred in subsequent cycles.
Efficacy measurements
Blood samples were obtained for complete blood counts
(CBCs). During cycle 1, CBC was measured daily from days
1 to 4, followed by daily measurements until ANC ≥1×109/L
post-nadir was achieved, and thereafter measured every 2 days
up to day 21. During all subsequent cycles, CBC was mea-
sured on days 1 to 3, 8, and 15. Axillary body temperature was
measured daily and recorded throughout the study.
The primary efficacy endpoint of this study was DSN,
which was defined as the number of days in which the patient
had an ANC <0.5×109/L during cycle 1 of TAC therapy. The
secondary efficacy endpoints included ANC profile, ANC na-
dir, and proportion of patients who developed FN in the first
cycle. FN was defined as an axillary body temperature ≥38 °C
with concurrent ANC <0.5×109/L.
Safety endpoints
The safety endpoints were incidence of adverse events, chang-
es in vital signs, and laboratory tests. Adverse events that
occurred after pegfilgrastim administration were documented.
Serum was collected at the beginning and end of the study to
detect antibodies capable of neutralizing the biological effects
of either pegfilgrastim or filgrastim.
Data sets and statistical analysis
The objective of this trial was to estimate the mean DSN in
order to determine the recommended dose of pegfilgrastim.
Efficacy and safety were assessed based on the per protocol
set and safety analysis set, respectively. Standard deviation of
DSN in each group was assumed to be 1.4, based on a previ-
ous trial [15]. With 22 patients in each group, the mean DSN
would be calculated with the standard error of approximately
0.3. Assuming that 10 % of patients would be withdrawn, the
planned total sample size was 75 patients (25 patients per
dosage group).
A three-contrast test was conducted in the dose response
analysis: linear reduction (1, 0, −1), reduction at 6.0 mg (1, 1,
−2), and plateau at 3.6 mg (2, −1, −1).
Adverse events were classified according to the Japanese
version of the Medical Dictionary for Regulatory Activities
preferred terms and were graded by severity according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events (version 3.0).




Between November 2009 and April 2010, a total of 90 Japa-
nese patients were randomized to the three pegfilgrastim dos-
age groups (30 patients per group). A total of 87 patients
received pegfilgrastim and were included in the per protocol
set and the safety analysis set. Three patients randomized to
each group (one each from the 1.8, 3.6, and 6.0 mg groups)
were excluded from the analysis of efficacy endpoints because
they withdrew from the study before receiving chemotherapy
or the study drug. Two of these patients withdrew because of
allergic reactions caused by docetaxel. One of these patients
could not receive TAC therapy because of health problems
and withdrew (Fig. 2).
A total of 13 patients withdrew from the study after receiv-
ing the study drug, including 5 (16.7 %) patients in the 1.8-mg
group, 5 (16.7 %) patients in the 3.6-mg group, and 3 (10.0 %)
patients in the 6.0-mg group. Of these patients, 1 patient in the
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1.8-mg group developed drug hypersensitivity (allergic reac-
tion to docetaxel) and discontinued the study. Two patients in
the 1.8-mg group, 1 patient in the 3.6-mg group, and 2 patients
in the 6.0-mg group were eliminated from the study because
of treatment changes. One patient in the 3.6-mg group with-
drew from the study because of progression of the primary
disease during neoadjuvant treatment. The other patients were
eliminated from the study because of informed consent with-
drawal. A total of 74 patients completed the trial.
Patient baseline characteristics are shown in Table 1. Pa-
tient characteristics were not different among the three dosage
groups. The median (range) age was 46.0 years (33–63 years),
47.0 years (26–64 years), and 48.0 years (26–64 years); the
mean body weight was 52.3, 56.3, and 53.2 kg; and the mean
body surface area was 1.50, 1.55, and 1.51 in the 1.8-, 3.6-,
and 6.0-mg groups, respectively. A median of 6 cycles of
chemotherapy was administered to all dosage groups.
Efficacy
In cycle 1 of TAC therapy, ANC decreased to <0.5×109/L in
28 (96.6 %) patients, 25 (86.2 %) patients, and 27 (93.1 %)
patients in the 1.8-, 3.6-, and 6.0-mg groups, respectively.
DSN (mean±standard deviation), the primary endpoint, was
2.2±0.9 days, 1.5±0.9 days, and 1.4±0.7 days in the 1.8-,
3.6-, and 6.0-groups, respectively (Fig. 3a). The dose-
response analysis, which was conducted based on the three-
contrast test, showed a reduction of DSN from 1.8- to 3.6-mg
pegfilgrastim followed by a plateau from 3.6 to 6.0 mg
(Bplateau from 3.6 mg^), with the smallest P value among
the three-contrast (P=0.001). Pegfilgrastim efficacy stratified
by chemotherapy setting (adjuvant or neoadjuvant) showed
similar dose responses.
FN occurred in 2 (6.9 %) patients in the 1.8-mg group, 3
(10.3 %) patients in the 3.6-mg group, and 1 (3.4 %) patient in
the 6.0-mg group with no statistically significant difference
between the groups (Table 2). In cycle 1 of TAC therapy, 1
patient in the 3.6-mg group received G-CSF on days 7 and 8
as rescue treatments.
Changes in the mean ANC in cycle 1 of TAC therapy are
shown in Fig. 3b. The mean ANC peaked on day 3 of study
drug administration in all groups, and nadir occurred on day 7 in
the 1.8-mg group and day 6 in the 3.6- and 6.0-mg groups. ANC
almost reached the baseline values after day 11 in all groups.
The ANC at nadir (mean±standard deviation) was 0.184±
0.212×109/L in the 1.8-mg group, 0.240±0.208×109/L in the
3.6-mg group, and 0.255±0.287×109/L in the 6.0-mg group
(Table 2).
Safety
All 87 patients experienced adverse events. Non-hematologic
adverse events that occurred in ≥50% of patients in all groups
were alopecia, nausea, malaise, constipation, dysgeusia, de-
creased appetite, vomiting, and diarrhea (Online Resource 1).
Fig. 2 Patient consort diagram
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Most of these events were considered to be associated with
TAC therapy.
No adverse events resulted in death. Serious non-fatal ad-
verse events occurred in four patients in the 1.8-mg group
(upper respiratory tract inflammation, cystitis, pneumonia,
and radius fracture) and 1 patient in the 6.0-mg group (de-
creased appetite and malaise).
Bone pain and back pain are common adverse events asso-
ciated with G-CSF. Bone pain occurred in 1 (3.4 %) patient in
each group. Throughout the course of chemotherapy, back
pain was observed in 3 (10.3 %) patients in the 1.8-mg group,
6 (20.7 %) patients in the 3.6-mg group, and 8 (27.6 %) pa-
tients in the 6.0-mg group. Because these adverse events were
grade 2 or lower in severity and could be controlled without
treatment or with non-steroidal anti-inflammatory drugs, there
were no safety concerns in any of the groups.
Hematologic adverse events
Grade 3 or 4 neutropenia occurred in 29 (100 %) patients in
the 1.8-mg group, 29 (100 %) patients in the 3.6-mg group,
and 28 (96.6 %) patients in the 6.0-mg group in all TAC
cycles. Grade 3 or 4 thrombocytopenia occurred in 4
(13.8 %) patients in the 3.6-mg group and 4 (13.8 %) patients
in the 6.0-mg group in all TAC cycles. Grade 3 or 4 anemia
occurred in 1 (3.4 %) patient in the 1.8-mg group and 1
(3.4 %) patient in the 6.0-mg group in all cycles (Table 3).
Antibody formation
Serum antibodies to pegfilgrastim or filgrastim were tested
using the BIAcore assay for all patients who received the
study drug; antibodies were not detected in any patients.
Discussion
DSN, the primary endpoint of this study, has been shown to be
well correlated with the incidence of FN [1, 2]. The European
Medicines Agency (formerly the European Medicines Evalu-
ation Agency) guidelines describe DSN as an acceptable sur-
rogate endpoint for the exploratory and confirmatory trials of
G-CSF [12]. According to these guidelines, DSN was set as
the primary endpoint of this study. In phase III studies con-
ducted in the USA, Canada, European countries, and Austra-
lia, pegfilgrastim administered at a 100 μg/kg dose or 6-mg
fixed dose regardless of body weight had a similar effect on
DSN [13, 14]. Based on these findings, pegfilgrastim at a
fixed dose of 6 mg is widely used in the world.
The safety of pegfilgrastim at doses of 30, 60, and 100 μg/
kg was evaluated in a clinical pharmacological study in Japa-
nese lung cancer patients [15]. The study results demonstrated
the safety and tolerability of a single subcutaneous
pegfilgrastim injection up to 100 μg/kg. In the present study,
three fixed pegfilgrastim doses of 1.8, 3.6, or 6.0 mg were
Table 1 Summary of demographic and baseline characteristics for patients evaluable for efficacy (per protocol set)
Pegfilgrastim
1.8 mg 3.6 mg 6.0 mg
n=29 n=29 n=29
Age (y) Median (range) 46.0 (33–63) 47.0 (26–64) 48.0 (26–64)
Body weight (kg) Mean±SD 52.3±6.7 56.3±9.3 53.2±8.4
<60 kg 25 (86.2 %) 18 (62.1 %) 24 (82.8 %)
≥60 kg 4 (13.8 %) 11 (37.9 %) 5 (17.2 %)
Body surface area (m2) Mean±SD 1.50±0.10 1.55±0.14 1.51±0.12
Chemotherapy Neoadjuvant 14 (48.3 %) 15 (51.7 %) 15 (51.7 %)
Adjuvant 15 (51.7 %) 14 (48.3 %) 14 (48.3 %)
Primary disease Infiltrating ductal carcinoma 28 (96.6 %) 27 (93.1 %) 26 (89.7 %)
Special type 1 (3.4 %) 2 (6.9 %) 3 (10.3 %)
Clinical stage IIA 10 (34.5 %) 10 (34.5 %) 12 (41.4 %)
IIB 14 (48.3 %) 9 (31.0 %) 11 (37.9 %)
IIIA, IIIB, IIIC 5 (17.2 %) 10 (34.5 %) 6 (20.7 %)
Lymph node involvement pN0 5 (17.2 %) 9 (31.0 %) 10 (34.5 %)
pN(+) 23 (79.3 %) 20 (69.0 %) 18 (62.1 %)
Unknown 1 (3.4 %) 0 (0 %) 1 (3.4 %)
ER and/or PgR(+) 20 (69.0 %) 20 (69.0 %) 21 (72.4 %)
ER and PgR(−) 9 (31.0 %) 9 (31.0 %) 8 (27.6 %)
ER estrogen receptor, PgR progesterone receptor, SD standard deviation
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used to determine the recommended pegfilgrastim dose in
Japanese patients with breast cancer. DSN was 2.2±0.9 days,
1.5±0.9 days, and 1.4±0.7 days in the 1.8-, 3.6-, and 6.0-mg
groups, respectively. Analysis of the dose-response relation-
ship between pegfilgrastim dose and DSN revealed a signifi-
cant Blinear reduction^ (P=0.005), significant Bplateau at
3.6 mg^ (P=0.001), and non-significant reduction at 6.0 mg
(P=0.092).
A dose-finding study of pegfilgrastim conducted in the
USA also showed a linear shortening of DSN in response
to pegfilgrastim (30, 60, or 100 μg/kg) injection in breast
cancer patients undergoing doxorubicin/docetaxel chemo-
therapy [16]. In a phase I trial in Japan, lung cancer pa-
tients undergoing chemotherapy received a single injec-
tion of pegfilgrastim if they experienced grade 4 neutro-
penia in the previous cycle [15]. In another phase I trial in
lung cancer patients conducted in the USA, single-dose
pegfilgrastim or daily filgrastim was administered 14 days
prior to initial chemotherapy dosing and again after che-
motherapy [17]. Both of these clinical trials revealed a
non-linear trend in pharmacokinetic parameters, such as
Cmax and area under the concentration curve. However,
differences in race, study design, and chemotherapy regi-
mens may have contributed to the discrepancy in
pegfilgrastim dose responses in these phase II trials. The
approved dose of filgrastim for chemotherapy-induced
neutropenia in Japan is one fourth to one half of the dose
approved in other foreign countries. Compared with the
approved pegfilgrastim dose of 6 mg in Europe and the
USA, lower pegfilgrastim doses provided adequate effica-
cy in Japanese patients undergoing chemotherapy.
Although different regimens were used, the DSN response
to 3.6-mg pegfilgrastim in Japanese patients in our study was
similar to the DSN response to 6.0-mg pegfilgrastim in phase
III trials conducted in the USA, Canada, European countries,
and Australia (1.5±0.9 days vs. 1.8±1.4 days) [13, 14]. Con-
sidering the difference in regimens and patient populations, as
well as the fact that the previous trials were conducted approx-
imately a decade ago, it is difficult to make cross-trial com-
parisons among these groups.
In the present study, all patients experienced adverse
events; however, most adverse events were associated with
cancer chemotherapy. Pegfilgrastim was well tolerated up to
6.0 mg.
Based on our results, 3.6 mg of pegfilgrastim may be a safe
and effective dose. However, because this study was conduct-
ed as an exploratory dose-finding study in Japanese patients, a
confirmatory study is required.
This study was conducted in breast cancer patients receiv-
ing TAC therapy. The BCIRG001 study compared the
Table 3 Grade 3 or 4 hematologic adverse events across all cycles
Pegfilgrastim
1.8 mg 3.6 mg 6.0 mg
n=29 n=29 n=29
Neutropenia 29 (100 %) 29 (100 %) 28 (96.6 %)
Leukocytopenia 29 (100 %) 28 (96.6 %) 28 (96.6 %)
Anemia 1 (3.4 %) 0 (0.0 %) 1 (3.4 %)
Thrombocytopenia 0 (0.0 %) 4 (13.8 %) 4 (13.8 %)
Lymphopenia 13 (44.8 %) 13 (44.8 %) 11 (37.9 %)
Data are presented as n (%)
Table 2 The incidence of FN and nadir of ANC (per protocol set)
Pegfilgrastim
1.8 mg 3.6 mg 6.0 mg
n=29 n=29 n=29
FNa n (%) 2 (6.9 %) 3 (10.3 %) 1 (3.4 %)
Nadir of ANC
(×109/L)
Mean±SD 0.184±0.212 0.240±0.208 0.255±0.287
FN febrile neutropenia, ANC absolute neutrophil count, SD standard
deviation
a FN was defined as body temperature ≥38 °C
Fig. 3 a Duration of severe neutropenia (DSN) in the first cycle. b
Median absolute neutrophil count (ANC) for cycle 1. SD standard
deviation
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efficacy and safety of TAC therapy and FAC (fluorouracil/
doxorubicin/cyclophosphamide) therapy as adjuvant che-
motherapy in 1047 node-negative breast cancer patients.
The BCIRG001 study showed that 5-year progression-free
survival and overall survival were significantly longer in
the TAC therapy group than in the FAC therapy group,
and this significant difference was maintained at 10 years
[18, 19]. At the time 237 subjects were enrolled, the in-
cidence of FN was significantly higher in the TAC thera-
py group than in the FAC therapy group (24.7 vs. 2.5 %;
P<0.001) [20]. Although the use of prophylactic antibi-
otics was initially mandated in the TAC therapy group,
the prophylactic use of G-CSF was not allowed. There-
fore, the study protocol was revised to specify the pro-
phylactic use of G-CSF in the TAC therapy group. Pro-
phylactic G-CSF decreased the incidence of FN in the
TAC therapy group from 24.7 to 6.5 %. Based on the
results of the BCIRG001 study, the National Comprehen-
sive Cancer Network guidelines indicate the use of
filgrastim support in all cycles of TAC therapy.
Because G-CSF is not currently indicated for the primary
prophylaxis of FN induced by breast cancer chemotherapies in
Japan, intensive chemotherapy regimens are rarely used in
Japan. If breast cancer is treated with intensive chemotherapy
regimens, such as TAC, which is commonly used in Europe
and the USA, a pre-planned dose reduction from the standard
dose is needed. Conversely, according to various reports, dose
reduction in cancer chemotherapy attenuates therapeutic ef-
fects [3–7]. It is important to administer cancer chemotherapy
at effective doses, as maintenance of relative dose intensity
may affect clinical outcomes, particularly in the adjuvant
setting.
In our study, TAC therapy with prophylactic pegfilgrastim
support was conducted safely, even in the outpatient setting.
The proportion of patients who developed FNwas 6.9 % in all
pegfilgrastim dosage groups. Prophylactic pegfilgrastim at a
fixed dose of 3.6 mg is expected to allow cancer chemother-
apy to be administered at the same dose intensity for Japanese
breast cancer patients as that used for patients in Western
countries.
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